Corona virus death toll in China rises to 811

China’s health archive reports an increase in deaths coronavirus to 180.

Chinese media reported that the Chinese National Public Health Commission confirmed on Sunday (April 20) that one of the infected (viral corona) died last night in Hubei Province, China.

Chinese media quoted the National Public Health Commission’s website as reporting on countries where the coronavirus had arrived in their country, urging them to use a mask to prevent the virus (coronavirus). However, reports from China indicate that the government has been satisfied with the acceptance of aid provided by the World Health Organization. However, the Chinese government had previously refused funding from the United States and the World Health Organization to eliminate the Coronavirus.

To date, more than 37,193 people have been infected with coronary artery disease in China.

Reporter: Shakib Zahir


Vaccines typically require years of research and testing before reaching the clinic, but scientists are racing to produce a safe and effective coronavirus vaccine by next year. Researchers are testing 38 vaccines in clinical trials on humans, and at least 93 preclinical vaccines are under active investigation in animals.

Work began in January with the deciphering of the SARS-CoV-2 genome. The first vaccine safety trials in humans started in March, but the road ahead remains uncertain. Some trials will fail, and others may end without a clear result. But a few may succeed in stimulating the immune system to produce effective antibodies against the virus.

Here is the status of all the vaccines that have reached trials in humans, along with a selection of promising vaccines still being tested in cells or animals.

For an overview of different Covid-19 treatments, see our Coronavirus Drug and Treatment Tracker.

PRECLINICAL TESTING: Scientists test a new vaccine on cells and then give it to animals such as mice or monkeys to see if it produces an immune response. We have confirmed 93 preclinical vaccines in active development.